27
Apr
2015
It’s Time to Re-Think How We Train and Develop Biomedical Scientists
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Apr
2015
See the Photos: Timmerman Report East Coast Launch Party
About nine months ago, I booked plane tickets for the whole family to go to Boston. The plan was to run the Boston Marathon, and maybe do a little sight-seeing. I didn’t realize at the time it would turn into a business trip. Oh, but it did, and what a great business-and-pleasure trip it was. After Timmerman Report went live... Read More
20
Apr
2015
Hungry for Cash, Academia Reaches For a Bigger Piece of Biotech Action
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Apr
2015
AACR Conference Preview: Five Themes To Watch In Immunotherapy
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Apr
2015
Who Should Biotech Pros Follow on Twitter?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Apr
2015
The Big Boys Love Kendall Square. Let’s Hope They Don’t Squeeze The Life Out of It
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Apr
2015
Which Big Public Investors Are ‘Crossing Over’ Into the Private Arena?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Apr
2015
Baseball Meets Biotech, Where Hope Springs Eternal
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Apr
2015
Will We Just Give Up on Federal Funding for Research? I Sure Hope Not
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Apr
2015
Sarepta’s Controversial CEO is Out, But Duchenne Muscular Dystrophy R&D is Rising
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Mar
2015
Cancer Combos Are the Way Forward. Will Drugmakers Put Patients First?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Mar
2015
See the Photos: Timmerman Report West Coast Launch Party
Entrepreneurs know what it’s like to dream big and take risk, so they naturally tend to support people who do the same. For that, I’m immensely thankful. I was blown away, and humbled, by the words of encouragement I heard last week at the Timmerman Report launch party in my hometown of Seattle. There was a great mixed crowd of... Read More
24
Mar
2015
Come to Pfizer Cambridge for the East Coast Launch Party
Timmerman Report is coming to Boston next month for, oh, two of the bigger events of my life. Please mark your calendars for the first event—the Timmerman Report East Coast Launch Party. It will be 4-6 pm Thursday, Apr. 16 at Pfizer Cambridge, 610 Main Street, Cambridge, Mass. This will be a free gathering to thank the first wave of... Read More
23
Mar
2015
Company Subscriptions: You Asked, and You Will Get
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Mar
2015
Salaries are Inching Up in the Biotech Boom, Not Booming
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Mar
2015
NASH is the Next Monster Pharmaceutical Market. Here Are The Players
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Mar
2015
Third Rock’s Revolution Medicines Tears Apart Antifungals, Atom By Atom
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Mar
2015
The Top 20 Early-Stage Biotech Investors (And 2 Resuscitated By the Boom)
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Mar
2015
Ember Therapeutics, After Shutting Down, Pools IP With Mariel
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Mar
2015
Antibiotic R&D Is Getting More Attention. Who’s Doing What?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.